EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions

Fang Ren, Jing Wei, Qingxin Chen, Mengling Hu, Lu Yu, Jianing Mi, Xiaogang Zhou, Dalian Qin, Jianming Wu, Anguo Wu

Acta Pharmaceutica Sinica B · 2025-09 · 15 (9) · 4327-4385

DOI: 10.1016/j.apsb.2025.07.030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-09. Verfasst von Fang Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and W…. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 434 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing Municipality, Southwest Medical University, Sichuan Province Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, with few effective treatments currently available. The multifactorial nature of AD, shaped by genetic, environmental, and biological factors, complicates both research and clinical management. Recent advances in artificial intelligence (AI) and multi-omics technologies provide new opportunities to elucidate the molecular mechanisms of AD and identify early biomarkers for diagnosis and prognosis. AI-driven approaches such as machine learning, deep learning, and network-based models have enabled the integration of large-scale genomic, transcriptomic, proteomic, metabolomic, and microbiomic datasets. These efforts have facilitated the discovery of novel molecular signatures and therapeutic targets. Methods including deep belief networks and joint deep semi-non-negative matrix factorization have contributed to improvements in disease classification and patient stratification. However, ongoing challenges remain. These include data heterogeneity, limited interpretability of complex models, a lack of large and diverse datasets, and insufficient clinical validation. The absence of standardized multi-omics data processing methods further restricts progress. This review systematically summarizes recent advances in AI-driven multi-omics research in AD, highlighting achievements in early diagnosis and biomarker discovery while discussing limitations and future directions needed to advance these approaches toward clinical application.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseArtificial intelligenceBiomarkersDeep learningDrug discoveryEarly detectionMachine learningMulti-omicsPathological mechanismsPersonalized treatment

Autor:innen und Institutionen

  • Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chon…
  • State Key Laboratory of Traditional Chinese Medicine Syndrome, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
  • Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Department of Cardiology, Department of Ophthalm…
  • Department of Pharmacy, Guang'an People's Hospital, Guangan 638550, China.

Förderung

  • Natural Science Foundation of Chongqing Municipality
  • Southwest Medical University
  • Sichuan Province Science and Technology Support Program
  • National Natural Science Foundation of China

Zitieren

APA

Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025). Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions. Acta Pharmaceutica Sinica B, 15(9), 4327-4385. https://doi.org/10.1016/j.apsb.2025.07.030

Vancouver

Ren F, Wei J, Chen Q, Hu M, Yu L, Mi J, et al. Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions. Acta Pharmaceutica Sinica B. 2025;15(9):4327-4385. doi:10.1016/j.apsb.2025.07.030

BibTeX
@article{Ren2025,
  author = {Ren, Fang and Wei, Jing and Chen, Qingxin and Hu, Mengling and Yu, Lu and Mi, Jianing and Zhou, Xiaogang and Qin, Dalian and Wu, Jianming and Wu, Anguo},
  title = {Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {9},
  pages = {4327--4385},
  doi = {10.1016/j.apsb.2025.07.030}
}
Kostenlos starten →